- Home
- MCRB vs SHMD Comparison
MCRB vs SHMD Comparison
Compare MCRB & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SHMD
- Stock Information
- Founded
- MCRB 2010
- SHMD 1864
- Country
- MCRB United States
- SHMD Germany
- Employees
- MCRB N/A
- SHMD N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SHMD
- Sector
- MCRB Health Care
- SHMD
- Exchange
- MCRB Nasdaq
- SHMD Nasdaq
- Market Cap
- MCRB 103.7M
- SHMD 123.6M
- IPO Year
- MCRB 2015
- SHMD N/A
- Fundamental
- Price
- MCRB $12.09
- SHMD $2.95
- Analyst Decision
- MCRB Hold
- SHMD
- Analyst Count
- MCRB 4
- SHMD 0
- Target Price
- MCRB $73.67
- SHMD N/A
- AVG Volume (30 Days)
- MCRB 107.4K
- SHMD 28.5K
- Earning Date
- MCRB 08-12-2025
- SHMD 02-25-2025
- Dividend Yield
- MCRB N/A
- SHMD N/A
- EPS Growth
- MCRB N/A
- SHMD N/A
- EPS
- MCRB 8.98
- SHMD N/A
- Revenue
- MCRB N/A
- SHMD $85,165,542.00
- Revenue This Year
- MCRB N/A
- SHMD N/A
- Revenue Next Year
- MCRB N/A
- SHMD N/A
- P/E Ratio
- MCRB $1.42
- SHMD N/A
- Revenue Growth
- MCRB N/A
- SHMD N/A
- 52 Week Low
- MCRB $6.53
- SHMD $1.86
- 52 Week High
- MCRB $30.60
- SHMD $4.98
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- SHMD N/A
- Support Level
- MCRB $10.67
- SHMD N/A
- Resistance Level
- MCRB $12.84
- SHMD N/A
- Average True Range (ATR)
- MCRB 1.09
- SHMD 0.00
- MACD
- MCRB 0.34
- SHMD 0.00
- Stochastic Oscillator
- MCRB 85.98
- SHMD 0.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).